Cyclic Nucleotide Signaling in Alzheimer's Disease Management

Alzheimer’s disease (AD) is marked by progressive cognitive impairment driven by synaptic dysfunction, amyloid-β aggregation, tau pathology and neurovascular compromise. Cyclic nucleotides—cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP)—serve as pivotal second messengers in the regulation of synaptic plasticity, gene transcription and vascular clearance mechanisms. Dysregulation of these pathways contributes to memory deficits and neuronal loss. Therapeutic strategies aim to restore cyclic nucleotide balance through receptor stimulation and inhibition of phosphodiesterases (PDEs), the enzymes responsible for cyclic nucleotide hydrolysis. Enhancement of cAMP signalling via β-adrenergic agonists or selective PDE4 inhibitors preserves hippocampal long-term potentiation (LTP) and mitigates amyloid-induced synaptic impairments. cGMP-elevating approaches, including PDE5 inhibitors and nitric oxide (NO) donors, support neuroprotection, promote perivascular drainage of amyloid and rescue tau-induced memory deficits. Repurposing approved PDE inhibitors holds practical appeal, offering a global framework to modulate intracellular signalling and slow AD progression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Cyclic Nucleotide Signaling in Alzheimer's Disease Management publication trend

The graph below shows the total number of articles in cyclic nucleotide signaling in alzheimer's disease management across all publications each year (not limited to Nature Index journals).

Technical terms

cAMP: Cyclic adenosine monophosphate, a second messenger activating protein kinase A to regulate synaptic plasticity and memory consolidation.

cGMP: Cyclic guanosine monophosphate, a second messenger activating protein kinase G to modulate neurovascular function and neuronal survival.

Phosphodiesterase (PDE): Enzymes that hydrolyse cyclic nucleotides; PDE4 preferentially degrades cAMP, while PDE5 targets cGMP.

Long-term potentiation (LTP): A durable increase in synaptic strength considered a cellular substrate for learning and memory.

β-adrenergic receptor agonist: A compound that stimulates β-adrenergic receptors, elevating intracellular cAMP levels to enhance neuronal signalling.

References

1. Inhibition of hippocampal mossy fiber plasticity and episodic memory by human Aβ oligomers is prevented by enhancing cAMP signaling in Alzheimer's mice. Alzheimer's & Dementia (2025).
2. Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer’s disease. Neuropsychopharmacology (2024).
3. PDE5 inhibitor drugs for use in dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions (2023).
4. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease. Neurology (2024).
5. Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. Molecular Neurodegeneration (2019).